Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1967 1
1968 1
1970 2
1971 1
1972 1
1973 1
1975 1
1976 2
1978 3
1979 2
1981 6
1982 3
1983 4
1984 3
1985 4
1986 3
1987 6
1988 3
1989 7
1990 2
1991 5
1992 13
1993 8
1994 5
1995 6
1996 7
1997 8
1998 6
1999 7
2000 11
2001 13
2002 19
2003 9
2004 13
2005 17
2006 15
2007 13
2008 23
2009 19
2010 30
2011 30
2012 27
2013 36
2014 53
2015 96
2016 99
2017 103
2018 97
2019 110
2020 90
2021 97
2022 107
2023 128
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

1,309 results

Results by year

Filters applied: . Clear all
Page 1
D-Dimer elevation and adverse outcomes.
Halaby R, Popma CJ, Cohen A, Chi G, Zacarkim MR, Romero G, Goldhaber SZ, Hull R, Hernandez A, Mentz R, Harrington R, Lip G, Peacock F, Welker J, Martin-Loeches I, Daaboul Y, Korjian S, Gibson CM. Halaby R, et al. J Thromb Thrombolysis. 2015 Jan;39(1):55-9. doi: 10.1007/s11239-014-1101-6. J Thromb Thrombolysis. 2015. PMID: 25006010 Free PMC article. Review.
D-Dimer is a biomarker of fibrin formation and degradation. While a D-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the pr …
D-Dimer is a biomarker of fibrin formation and degradation. While a D-dimer within normal limits is used to rule out the diagn …
Discovery, characterization, and clinical development of the glucagon-like peptides.
Drucker DJ, Habener JF, Holst JJ. Drucker DJ, et al. J Clin Invest. 2017 Dec 1;127(12):4217-4227. doi: 10.1172/JCI97233. Epub 2017 Dec 1. J Clin Invest. 2017. PMID: 29202475 Free PMC article. Review.
The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine. Herein, we provid …
The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contribut …
The Reply.
Krittanawong C, Maitra NS, Virk HUH, Fogg S, Wang Z, Gritsch D, Storch EA, Tobler PN, Charney DS, Levine GN. Krittanawong C, et al. Am J Med. 2022 Dec;135(12):e440. doi: 10.1016/j.amjmed.2022.08.025. Am J Med. 2022. PMID: 36404056 No abstract available.
RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.
Compadre AJ, van Biljon LN, Valentine MC, Llop-Guevara A, Graham E, Fashemi B, Herencia-Ropero A, Kotnik EN, Cooper I, Harrington SP, Kuroki LM, McCourt CK, Hagemann AR, Thaker PH, Mutch DG, Powell MA, Sun L, Mosammaparast N, Serra V, Zhao P, Lomonosova E, Khabele D, Mullen MM. Compadre AJ, et al. Clin Cancer Res. 2023 Jul 5;29(13):2466-2479. doi: 10.1158/1078-0432.CCR-22-3335. Clin Cancer Res. 2023. PMID: 37097615 Free PMC article.
Paul Randall Harrington, M.D., 1911-1980.
[No authors listed] [No authors listed] J Bone Joint Surg Am. 1981 Jun;63(5):857. J Bone Joint Surg Am. 1981. PMID: 7016886 No abstract available.
New Biologics for Asthma.
Drazen JM, Harrington D. Drazen JM, et al. N Engl J Med. 2018 Jun 28;378(26):2533-2534. doi: 10.1056/NEJMe1806037. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782236 No abstract available.
Noninvasive monitoring.
Harrington GR, Hnatiuk OW. Harrington GR, et al. Am J Med. 1993 Aug;95(2):221-8. doi: 10.1016/0002-9343(93)90264-p. Am J Med. 1993. PMID: 8356987 Review.
The FDA and the Importance of Trust.
Baden LR, Solomon CG, Greene MF, D'Agostino RB, Harrington D. Baden LR, et al. N Engl J Med. 2020 Dec 31;383(27):e148. doi: 10.1056/NEJMe2030687. Epub 2020 Sep 30. N Engl J Med. 2020. PMID: 32997901 No abstract available.
Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CK, Conti D, Harrington P, Fraser L, Philpott S, Anderson C, Rosenthal A, Gentry-Maharaj A, Bowtell DD, Alsop K, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Høgdall E, Høgdall CK, Jensen A, Kjaer SK, Lubiński J, Huzarski T, Jakubowska A, Gronwald J, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Odunsi K, Goode EL, Menon U, Jacobs IJ, Gayther SA, Pharoah PD. Song H, et al. J Clin Oncol. 2015 Sep 10;33(26):2901-7. doi: 10.1200/JCO.2015.61.2408. Epub 2015 Aug 10. J Clin Oncol. 2015. PMID: 26261251 Free PMC article.
Atherothrombosis: Seeing Red?
Simon DI, Silverstein RL. Simon DI, et al. Circulation. 2015 Nov 17;132(20):1860-2. doi: 10.1161/CIRCULATIONAHA.115.019259. Epub 2015 Oct 14. Circulation. 2015. PMID: 26467255 Free PMC article. No abstract available.
1,309 results